Clinical Trials Directory

Trials / Completed

CompletedNCT00660647

Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)

Optimized Treatment Algorithm in Early Rheumatoid Arthritis: Methotrexate and Intra-articular Glucocorticosteroid Plus Adalimumab or Placebo in the Treatment of Early Rheumatoid Arthritis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
180 (actual)
Sponsor
University of Aarhus · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. Optimized Treatment Algorithms for Patients with Early RA

Detailed description

In newly diagnosed rheumatoid arthritis patients it is recommended to treat as soon as possible with methotrexate and steroids However, this treatment algorithm, will only bring one third of the patients into remission and cannot stop progressive, persistent joint damage. The possible benefits and risks of adding adalimumab to this conventional treatment algorithm is unknown. The aim of the study is to clarify the possible benefits of adding adalimumab an anti-TNF-alfa inhibitor versus placebo to the treatment of rheumatoid arthritis patients, who are treated very early and given methotrexate and intraarticular triamcinolone hexacetonide. Efficacy will be evaluated by DAS 28, ACR 20/50/70, HAQ, progressive changes in X-ray, MRI and DXA-scans. Adverse events will also be registered.

Conditions

Interventions

TypeNameDescription
DRUGAdalimumabAdalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
DRUGPlaceboSaline injection 0.9%, 0.8 ml s.c. every second week up to 2 years

Timeline

Start date
2007-09-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2008-04-17
Last updated
2015-11-24

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT00660647. Inclusion in this directory is not an endorsement.